Lotus Pharmaceutical Co Ltd (1795) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.112x

Based on the latest financial reports, Lotus Pharmaceutical Co Ltd (1795) has a cash flow conversion efficiency ratio of 0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$2.47 Billion ≈ $77.90 Million USD) by net assets (NT$22.17 Billion ≈ $698.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Lotus Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Lotus Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Lotus Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.

Lotus Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lotus Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Americas Silver Corp TO:USA	-0.213x
Atea ASA OL:ATEA	-0.248x
Thanachart Capital Public Company Limited BK:TCAP	0.040x
Ducommun Incorporated NYSE:DCO	0.028x
GCM Grosvenor Inc NASDAQ:GCMG	0.223x
Alten SA PA:ATE	0.091x
CoreCivic Inc NYSE:CXW	0.000x
SUEDZUCKER UNSP.ADR 1/2 F:SZU1	N/A

Annual Cash Flow Conversion Efficiency for Lotus Pharmaceutical Co Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Lotus Pharmaceutical Co Ltd from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Lotus Pharmaceutical Co Ltd (1795) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	NT$21.18 Billion ≈ $667.30 Million	NT$6.15 Billion ≈ $193.91 Million	0.291x	+212.04%
2023-12-31	NT$17.33 Billion ≈ $546.10 Million	NT$1.61 Billion ≈ $50.86 Million	0.093x	-65.28%
2022-12-31	NT$13.87 Billion ≈ $436.91 Million	NT$3.72 Billion ≈ $117.18 Million	0.268x	+2380.88%
2021-12-31	NT$11.07 Billion ≈ $348.73 Million	NT$119.66 Million ≈ $3.77 Million	0.011x	-95.15%
2020-12-31	NT$8.75 Billion ≈ $275.53 Million	NT$1.95 Billion ≈ $61.39 Million	0.223x	+469.83%
2019-12-31	NT$7.74 Billion ≈ $243.97 Million	NT$302.81 Million ≈ $9.54 Million	0.039x	-62.31%
2018-12-31	NT$7.68 Billion ≈ $241.98 Million	NT$796.98 Million ≈ $25.11 Million	0.104x	+34.84%
2017-12-31	NT$7.70 Billion ≈ $242.50 Million	NT$592.29 Million ≈ $18.66 Million	0.077x	-47.82%
2016-12-31	NT$8.36 Billion ≈ $263.42 Million	NT$1.23 Billion ≈ $38.85 Million	0.147x	+19.48%
2015-12-31	NT$8.73 Billion ≈ $275.06 Million	NT$1.08 Billion ≈ $33.95 Million	0.123x	+205.33%
2014-12-31	NT$8.81 Billion ≈ $277.59 Million	NT$-1.03 Billion ≈ $-32.53 Million	-0.117x	-81.88%
2013-12-31	NT$1.49 Billion ≈ $46.87 Million	NT$-95.84 Million ≈ $-3.02 Million	-0.064x	+24.60%
2012-12-31	NT$637.28 Million ≈ $20.08 Million	NT$-54.45 Million ≈ $-1.72 Million	-0.085x	+33.24%
2011-12-31	NT$596.05 Million ≈ $18.78 Million	NT$-76.29 Million ≈ $-2.40 Million	-0.128x	-239.89%
2010-12-31	NT$646.95 Million ≈ $20.38 Million	NT$59.19 Million ≈ $1.86 Million	0.091x	-53.31%
2009-12-31	NT$456.73 Million ≈ $14.39 Million	NT$89.50 Million ≈ $2.82 Million	0.196x	--

About Lotus Pharmaceutical Co Ltd

TW:1795 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$1.83 Billion

NT$58.08 Billion TWD

Market Cap Rank

#6612 Global

#186 in Taiwan

Share Price

NT$221.00

Change (1 day)

+0.23%

52-Week Range

NT$186.00 - NT$363.00

All Time High

NT$363.00